ID   KBM-3
AC   CVCL_A425
SY   KBM3
DR   ChEMBL-Cells; CHEMBL3307847
DR   ChEMBL-Targets; CHEMBL614010
DR   Cosmic; 975260
DR   Wikidata; Q54899582
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=1568450;
RX   PubMed=1995877;
CC   Doubling time: 22.9 hours, at 255th passage (PubMed=1568450).
CC   Derived from sampling site: Peripheral blood.
DI   NCIt; C7463; Acute myelomonocytic leukemia
DI   ORDO; Orphanet_517; Acute myelomonocytic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Female
AG   32Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 12-03-20; Version: 11
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=1568450;
RA   Andersson B.S., Bergerheim U.S.R., Collins V.P., Childs C., Beran M.,
RA   Sen S., Arden K., Pathak S., Siciliano M.J., Ost A., Freireich E.J.;
RT   "KBM-3, an in vitro model of human acute myelomonocytic leukemia.";
RL   Exp. Hematol. 20:361-367(1992).
//
RX   PubMed=1995877; DOI=10.1021/jm00106a013;
RA   Farquhar D., Newman R.A., Zuckerman J.E., Andersson B.S.;
RT   "Doxorubicin analogues incorporating chemically reactive
RT   substituents.";
RL   J. Med. Chem. 34:561-564(1991).
//